ArticleJournal of clinical medicine2020

Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study.

Anwaar Saeed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.